Natalizumab

Good News for Women with MS: Disease May Not Worsen After Pregnancy After All

Retrieved on: 
Thursday, March 7, 2019
Medicine, Medical specialties, Multiple sclerosis, Organ systems, Immunosuppressants, Medical terminology, Neurological disorders, Natalizumab, Fingolimod, Symptom, Disease, Clinically isolated syndrome

Most people with MS have the relapsing-remitting form of the disease, where symptoms flare up, then go into periods of remission.

Key Points: 
  • Most people with MS have the relapsing-remitting form of the disease, where symptoms flare up, then go into periods of remission.
  • "We wanted to see if this information about an increase in attacks after giving birth still held true today," she said.
  • At the start of pregnancy, a total of 15 percent had clinically isolated syndrome, which is the first episode of MS symptoms.
  • A limitation of the study was that of all participants, few were treated with natalizumab or fingolimod prior to pregnancy.

Abreos Biosciences Announces Partnership with CLIA/CAP Certified Laboratory, ResearchDx

Retrieved on: 
Thursday, August 30, 2018
Immunosuppressants, Natalizumab, Chemistry, Pharmacology, Assay, Therapeutic drug monitoring, Health care

Together with ResearchDx, Abreos has developed moNATor, its first commercial product for therapeutic drug monitoring of Tysabri (Natalizumab).

Key Points: 
  • Together with ResearchDx, Abreos has developed moNATor, its first commercial product for therapeutic drug monitoring of Tysabri (Natalizumab).
  • "We are excited to launch the moNATor assay for the monitoring of therapeutic levels of Tysabri (Natalizumab)" said Shelly Gunn MD, PhD.
  • "The moNATor assay represents a new, highly sensitive class of assays designed to monitor levels of active drugs in the blood.
  • Abreos Biosciences, a San Diego-based biotech company was founded in 2013 by CEO Dr. Bradley Messmer and is focused on developing technologies in precision medicine using their proprietary Veritope platform.

FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients

Retrieved on: 
Friday, May 11, 2018
Immunology, Cytokines, Medicine, Immunosuppressants, Multiple sclerosis, Antivirals, Interferon beta-1a, Interferon, Fingolimod, Multiple sclerosis drug pipeline, Natalizumab

This is the first FDA approval of a drug to treat MS in pediatric patients.

Key Points: 
  • This is the first FDA approval of a drug to treat MS in pediatric patients.
  • "Multiple sclerosis can have a profound impact on a child's life.
  • This approval represents an important and needed advance in the care of pediatric patients with multiple sclerosis."
  • The clinical trial evaluating the effectiveness of Gilenya in treating pediatric patients with MS included 214 evaluated patients aged 10 to 17 and compared Gilenya to another MS drug, interferon beta-1a.